Biora Therapeutics, Inc., a biotechnology company, engages in developing oral biotherapeutics. The company's targeted therapeutics program uses an ingestible smart capsule for targeted delivery of therapeutics in the gastrointestinal (GI) tract to enhance the treatment of inflammatory bowel diseases; and systemic therapeutics program uses an ingestible capsule for needle-free delivery of biotherapeutics directly into the intestinal mucosa for enhanced systemic uptake. It is also developing diagnostics devices to help characterize the GI tract and diagnose GI diseases, such as small intestine bacterial overgrowth through the development of various technologies to diagnose at the site of the disease. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Harry Stylli

Paul W. Hawran

Biora Therapeutics, Inc.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Mark Skolnick

Walter Gilbert

Kevin Kimberlin

Peter D. Meldrum

Myriad Genetics, Inc.

Biora Therapeutics is reimagining therapeutics by creating smart pills designed for 
- targeted drug delivery to the GI tract, and 
- systemic, needle-free delivery of biotherapeutics
we are developing therapies to improve patients’ lives. 

At Biora, we envision a world where patients have access to needle-free drug delivery and better therapeutic outcomes. We welcome you to learn more about our mission and our guiding principles at https://bioratherapeutics.com/company/about

Biora Therapeutics

Biora Therapeutics Q3 corporate update to be held on November 13: https://lnkd.in/dm7wYB5J

Biora Therapeutics presents new data on the BioJet platform at #EASD2023 https://lnkd.in/gfRHf8gJ 
#drugdelivery

Biora Therapeutics announces submission of IND application to the FDA for BT-600 program https://lnkd.in/d26etYKu #IBD #UC #ulcerativecolitis

Dr. Shaoying Nikki Lee presented data from the NaviCap™ targeted oral delivery platform to IBD researchers at the Crohn's & Colitis Foundation Researcher Symposium in New York City this week. #IBD #ulcerativecolitis #drugdelivery

Biora Therapeutics progresses its BioJet™ systemic oral delivery platform https://lnkd.in/gx8NfFwz #oraldelivery #biologics #needlefree #drugdelivery

Biora Therapeutics provides corporate update and reports second quarter 2023 financial results: https://lnkd.in/gQWCHdKe

Announcing successful clinical device performance study results for our NaviCap™ targeted oral delivery platform #IBD #UC #ulcerativecolitis  https://lnkd.in/e7fqQSvx

See this week's feature in the San Diego Business Journal highlighting our BioJet™ systemic delivery platform: https://lnkd.in/gYDTAWDK #oraldelivery #biologics #needlefree
#drugdelivery

Biora Therapeutics announces new patents for its NaviCap™ targeted oral delivery platform  https://lnkd.in/gpD-xZnf #IP

Congrats to the authors who were at the American Diabetes Association sharing bioavailability data for orally-delivered GLP-1 receptor agonist. If you haven't seen the poster yet, download it here:  https://lnkd.in/gR_S6biY #ADA2023 #oraldelivery #biologics #needlefree
#drugdelivery

Metric
Company Name	Biora Therapeutics, Inc.	Myriad Genetics, Inc.
Symbol	BIOR	MYGN
MSH ID	COM:BIORATHERAPEUTICS	COM:MYRIAD
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Biotechnology	Medical - Diagnostics & Research
Country	US	US
Stage
Employee Count	58	2.70K
Website	bioratherapeutics.com	myriad.com
LinkedIn	biora-therapeutics
Founders

Metric
Market Cap	23.40M	2.28B
Enterprise Value
Monthly Web Traffic		208.71K
Web Traffic Growth		0.45
Valuation
Raised Capital		90M

Metric
Revenue	4K	678.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	4K	476.40M
EBITDA	-66.92M	-67.80M
Operating Income	-67.14M	-123.70M
Net Income	-124.11M	-112M
EPS	-7.87	-1.39
Diluted EPS	-7.87	-1.39
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80	0.69
Operating Profit Margin	-39.24	-0.37
EBITDA Margin	-16.73K	-0.10
Net Profit Margin	-49.99	-0.37
Return on Equity	1.15	-0.25
Return on Assets	-3.65	-0.15
Return on Capital Employed	2.45	-0.18

COM:BIORATHERAPEUTICS

Biora Therapeutics, Inc.

Last Close

1.63

22/11 21:00

Market Cap

23.40M

Beta: -

Volume Today

82.22K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.11	-6.54
P/B Ratio	-0.11	2.63
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	6.71K	6.58
EV Multiple	0.53	-7.65

Metric
Days Sales Outstanding	16.59K	57.25
Days Payables Outstanding		54.15
Days Inventory Outstanding	3.48K	79.39
Operating Cycle	75.74K	191.40
Cash Conversion Cycle	73.87K	84.17
Asset Turnover	0.09	0.64

Metric
Operating Cash Flow	-48.50M	-110.90M
Free Cash Flow	-48.60M	-184.20M
Cash Flow to Debt	-0.56	-0.11
Operating Cash Flow/Sales	-21.52	-0.06
Free Cash Flow Yield	-1.89	-0.08

Metric
Cash & Equivalents	15.21M	132.10M
Accounts Receivable		3.80M
Inventory		22M
Goodwill	6.07M	287.40M
Debt to Capitalization	-0.82	0.23
Debt to Assets	2.37	0.18
Current Ratio	0.28	1.27
Quick Ratio	0.28	1.15

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	949.72	0.05
R&D to Revenue	1.64K	0.12
SG&A to Revenue	464.22	0.94